Login to Your Account

AASLD Roundup

Tuesday, November 13, 2012
• Galectin Therapeutics Inc., of Norcross, Ga., presented preclinical data on the mechanism of action of GR-MD-02, its lead galectin inhibitor in non-alcoholic steatohepatitis (NASH), or fatty liver disease. Galectin-3 protein expression was markedly increased in animals with NASH, and those levels were reduced to barely detectable levels following treatment with GR-MD-02.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription